Roger Stock Price, News & Analysis

Rogers Corporation (NYSE:ROG) reported a strong Q1 2021, with net sales rising to $229.3 million, an 8.8% increase from Q4 2020. The growth was driven by demand in Advanced Mobility markets and industrial recovery. Gross margin improved to 39.0%, resulting in a diluted EPS of $1.66. However, the company anticipates supply chain disruptions will temper Q2 growth. Looking ahead, Rogers is expanding capacity to leverage growth opportunities in EV/HEV and other markets.

Rogers Corporation (NYSE: ROG) has appointed Ram Mayampurath as its new Senior Vice President, Chief Financial Officer, and Treasurer, effective May 1, 2021. Mayampurath replaces Michael Ludwig, who is retiring but will assist during the transition. Mayampurath has been with Rogers since 2014, holding senior leadership roles in financial operations and planning. His experience includes a decade-long career at Royal Phillips Electronics. President and CEO Bruce D. Hoechner expressed confidence in Mayampurath's capabilities to drive the company's growth and strategic goals.

Rogers Corporation (NYSE:ROG) will announce its first quarter 2021 results on April 29 after market close. A conference call will take place at 5:00 pm ET, featuring President and CEO Bruce Hoechner, along with SVP and CFO Mike Ludwig and SVP and CTO Bob Daigle. A live webcast and slide presentation will be available on the company's investor relations page. Rogers, with over 180 years of materials science experience, focuses on engineered materials for advanced connectivity and mobility applications, among other critical technologies.

Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the discontinuation of dosing in the Phase III GENERATION HD1 study of tominersen for Huntington’s disease based on data reviewed by an Independent Data Monitoring Committee. While no new safety signals were identified, the study’s potential benefit/risk profile led to this decision. The open-label extension study (GEN-EXTEND) will also pause dosing for further analysis. Genentech aims to continue following participants for safety and outcomes, sharing insights within the HD community once full data is analyzed.

Genentech, part of Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the Phase III IMpower010 study of Tecentriq^® (atezolizumab) met its primary endpoint of disease-free survival (DFS) in non-small cell lung cancer (NSCLC) patients at interim analysis. Significant DFS improvement was observed, especially in PD-L1-positive patients. Follow-up analyses will assess overall survival data. Tecentriq's safety profile remained consistent. Data will be presented at medical meetings and submitted to regulatory authorities for further evaluation.

Genentech, part of Roche Group (SIX: RO, ROG; OTCQX: RHHBY), released promising 2-year results from the SUNFISH study on Evrysdi™ (risdiplam) for Type 2 and non-ambulant Type 3 spinal muscular atrophy (SMA) in patients aged 2-25. Improvements in motor function achieved at 12 months were maintained or enhanced at 24 months across primary and secondary endpoints. The study, presented at the 2021 MDA Conference, showed no new safety signals. The findings reinforce Evrysdi's potential long-term benefits and favorable risk profile for SMA patients.

Genentech announced that the global Phase III REMDACTA study of Actemra (tocilizumab) plus Veklury (remdesivir) for treating severe COVID-19 pneumonia did not meet its primary endpoint of improved hospital discharge time. No new safety signals were reported for Actemra. The study, conducted with Gilead Sciences, failed to meet key secondary endpoints as well. Previous studies COVACTA did not meet its primary endpoint, while EMPACTA did. Genentech remains committed to evaluating the overall data for potential application of Actemra in COVID-19 treatments.

Genentech has announced the voluntary withdrawal of Tecentriq® (atezolizumab) from the U.S. market for prior-platinum treated metastatic urothelial carcinoma (mUC), following FDA consultation. This decision follows the failure of the IMvigor211 study to meet its primary overall survival endpoint. Genentech emphasizes that other approved indications for Tecentriq remain unaffected. The withdrawal reflects the evolving treatment landscape and aims to uphold the integrity of the FDA's Accelerated Approval Program.

Genentech announced FDA approval for Actemra® (tocilizumab) subcutaneous injection to slow pulmonary function decline in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This marks the first biologic therapy approved for this condition, impacting approximately 75,000 patients in the U.S. Key findings from the focuSSced Phase III trial indicated that Actemra reduced lung function decline compared to placebo, although the primary endpoint related to skin fibrosis was not met.

Common side effects included infections, aligning with Actemra's known safety profile.